2019
Slowly progressive fatal PML-IRIS following antiretroviral initiation at CD4+ nadir of 350 cells/mm3 despite CD4+ cell count rise to 900 cells/mm3
Sandhu MR, Rutledge R, Grant M, Mahajan A, Spudich S. Slowly progressive fatal PML-IRIS following antiretroviral initiation at CD4+ nadir of 350 cells/mm3 despite CD4+ cell count rise to 900 cells/mm3. International Journal Of STD & AIDS 2019, 30: 810-813. PMID: 31046614, DOI: 10.1177/0956462419835966.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAntiretroviral Therapy, Highly ActiveBrainCD4 Lymphocyte CountDisease ProgressionDystonic DisordersFatal OutcomeHIV InfectionsHumansImmune Reconstitution Inflammatory SyndromeJC VirusLeukoencephalopathy, Progressive MultifocalMagnetic Resonance ImagingMaleTreatment OutcomeConceptsImmune reconstitution inflammatory syndromePML-IRISAntiretroviral therapyCell countInflammatory syndromeInitiation of ARTHIV/AIDS patientsReconstitution inflammatory syndromeRobust immune reconstitutionCells/mm3Progressive multifocal leukoencephalopathyRole of CD4Blood-brain barrierCells/Antiretroviral initiationInflammatory picturePersistent positivityImmune reconstitutionMultifocal leukoencephalopathyNeurological symptomsOpportunistic infectionsAIDS patientsVirus antigenImmune responseJC virus
2016
Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection
Ananworanich J, Sacdalan CP, Pinyakorn S, Chomont N, Souza M, Luekasemsuk T, Schuetz A, Krebs SJ, Dewar R, Jagodzinski L, Ubolyam S, Trichavaroj R, Tovanabutra S, Spudich S, Valcour V, Sereti I, Michael N, Robb M, Phanuphak P, Kim JH, Phanuphak N, Group O. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. Journal Of Virus Eradication 2016, 2: 43-48. PMID: 26889497, PMCID: PMC4754199, DOI: 10.1016/s2055-6640(20)30688-9.Peer-Reviewed Original ResearchCD4/CD8 ratioAcute HIV infectionWeeks of ARTCD4 cell countFiebig ICD8 ratioT cellsThai Red Cross Anonymous ClinicCell countEarly acute HIV infectionPlasma interleukin-6 levelsImmune activation levelsLow HIV burdenLow HIV RNALow immune activationMedian HIV DNAPlasma sCD14 levelsMedian CD4 countInterleukin-6 levelsYears of ARTI individualsAHI participantsAnonymous ClinicFiebig stagesCD4 count
2008
Failure of atorvastatin to modulate CSF HIV-1 infection
Probasco JC, Spudich SS, Critchfield J, Lee E, Lollo N, Deeks SG, Price RW. Failure of atorvastatin to modulate CSF HIV-1 infection. Neurology 2008, 71: 521-524. PMID: 18695163, PMCID: PMC2676982, DOI: 10.1212/01.wnl.0000325006.84658.e7.Peer-Reviewed Original ResearchConceptsHIV-1 infectionHIV-1 RNA levelsT-cell countsCell countIntrathecal immunoactivationNeopterin concentrationsBlood lipidsBlood HIV-1 RNA levelCSF HIV-1 RNA levelsCSF white blood cell countCNS HIV-1 infectionSystemic HIV-1 infectionSingle-arm pilot studyWhite blood cell countPilot studyAntiretroviral-naïve subjectsCells/mulRNA levelsUntreated systemic infectionT-lymphocyte countsSmall uncontrolled studiesEffect of atorvastatinHMG-CoA reductase inhibitorsWeeks of treatmentHIV-1 RNA
2007
Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy
Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. The Journal Of Infectious Diseases 2007, 196: 1779-1783. PMID: 18190258, DOI: 10.1086/523648.Peer-Reviewed Original ResearchConceptsHIV RNA levelsCopies/mLActive antiretroviral therapyIntrathecal immunoactivationNeopterin levelsCerebrospinal fluidIgG indexAntiretroviral therapyPlasma HIV RNA levelsMacrophage/microglia activationHuman immunodeficiency virus (HIV) RNAUpper normal reference valueIntrathecal immunoglobulin productionYears of treatmentCentral nervous systemNormal reference valuesMicroglia activationImmune activationImmunoglobulin productionEffective treatmentCSF samplesPatientsNervous systemCell countHAART
2006
Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1–Infected Patients with Detectable Viremia
Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1–Infected Patients with Detectable Viremia. The Journal Of Infectious Diseases 2006, 194: 926-930. PMID: 16960780, DOI: 10.1086/507312.Peer-Reviewed Original ResearchConceptsT-cell countsX4-tropic virusesCXCR4-tropic virusesDetectable viremiaCell countUntreated human immunodeficiency virusHIV-1-infected patientsClinic-based cohortTreatment-naive participantsT-cell depletionHuman immunodeficiency virusViral coreceptor usageCXCR4 tropismSalvage therapySignificant CD4Advanced immunodeficiencyImmunodeficiency virusCell depletionCoreceptor usageCCR5 inhibitorsLow pretreatmentViremiaCD4VirusPatients
2005
HIV-1 Chemokine Coreceptor Utilization in Paired Cerebrospinal Fluid and Plasma Samples: A Survey of Subjects with Viremia
Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, Price RW. HIV-1 Chemokine Coreceptor Utilization in Paired Cerebrospinal Fluid and Plasma Samples: A Survey of Subjects with Viremia. The Journal Of Infectious Diseases 2005, 191: 890-898. PMID: 15717264, DOI: 10.1086/428095.Peer-Reviewed Original ResearchConceptsCerebrospinal fluidImmunodeficiency syndrome dementia complexCD4 T-cell countHuman immunodeficiency virus type 1 (HIV-1) entryMixture of R5Paired Cerebrospinal FluidT-cell countsPlasma samplesSurvey of subjectsHIV-1 populationsAdvanced immunodeficiencyCoreceptor utilizationInhibitor therapyPrincipal coreceptorR5 phenotypeX4 virusesDementia complexR5 virusesR5 tropismChemokine receptorsInfection pathogenesisCell countViral tropismDiscordant tropismCell tropism